AMPK–SQSTM1 Feedback Under Metabolic Stress

Study Background and Research Question

Metabolic stress in tumors is not limited to nutrient scarcity. Glucose depletion can reduce the production of NADPH and ATP, while the resulting oxidative burden can damage mitochondrial respiration and further intensify energy stress. Cancer cells therefore require coordinated systems that preserve energy balance, control reactive oxygen species (ROS), and maintain biosynthetic capacity. The STK11/LKB1–AMPK pathway is central to this adaptation because AMPK reduces energy consumption and promotes pathways that restore ATP and NADPH availability.

A second stress-response axis is governed by KEAP1 and NFE2L2/NRF2. When KEAP1-dependent degradation is reduced, NRF2 accumulates and induces antioxidant and cytoprotective genes. The clinical and biological problem addressed by the study is particularly relevant to non-small cell lung cancer: tumors with STK11/LKB1 mutations may acquire KEAP1 alterations that activate NRF2 and compensate for impaired AMPK signaling. The reference study asked how these two pathways communicate during metabolic stress and whether SQSTM1/p62 serves as a functional connector. The authors’ central observations are reported in the Autophagy study.

Key Innovation from the Reference Study

The major innovation is the identification of a double-positive feedback loop rather than a one-way stress response. Metabolic stress increased both the abundance and phosphorylation of SQSTM1/p62. In turn, SQSTM1 activated two protective pathways: it promoted autophagic degradation of KEAP1, releasing NFE2L2/NRF2, and it supported formation of the AXIN–STK11–AMPK complex at the lysosomal membrane, increasing AMPK activation.

The reciprocal component is equally important. AMPK activity was required for the metabolic-stress-induced increase in SQSTM1 expression and phosphorylation. Thus, SQSTM1 helps activate AMPK, while AMPK helps sustain SQSTM1. This architecture explains how a transient nutrient or lysosomal disturbance could become a durable adaptive state. It also offers a mechanistic interpretation of why STK11 and KEAP1 alterations may co-occur: loss of one protective branch can increase selective pressure for activation of the other.

The study further separates SQSTM1 abundance from SQSTM1 function. Expression was linked to lysosomal signaling involving TFEB and TFE3, whereas phosphorylation was connected to MAP3K7/TAK1 activation. The results therefore position SQSTM1 as an integrator of transcriptional, lysosomal, redox, and calcium-dependent signals rather than simply an autophagy adaptor.

Methods and Experimental Design Insights

The experimental strategy was built around controlled metabolic stress and pathway dissection. Low-nutrient or low-glucose conditions were used to model the metabolic environment in which AMPK and lysosomal signaling become engaged. The study then examined SQSTM1 expression and phosphorylation alongside AMPK and NRF2 pathway activity. This design is useful because it tests both the initiating stress response and the persistence of the response after pathway perturbation.

Mechanistic experiments addressed the two branches of SQSTM1 action. For the NRF2 branch, the authors evaluated whether KEAP1 was removed through macroautophagic degradation. For the AMPK branch, they examined the assembly of the AXIN–STK11–AMPK complex on lysosomal membranes. Protein-interaction and phosphorylation analyses were particularly important because total protein abundance alone would not establish complex formation or activation-state regulation.

The lysosomal mechanism was investigated through perturbations of acidification and proton handling. The reported use of lysosomal acidification perturbations, including bafilomycin A1 and concanamycin A in the experimental framework, helped connect low-glucose metabolism and AMPK-dependent proton reduction with lysosomal deacidification. The study also considered calcium release through MCOLN1/TRPML1, ROS dependence, and the role of MAP3K7/TAK1. Antioxidant intervention with N-acetylcysteine provided a way to test whether ROS was upstream of the phosphorylation response rather than merely a consequence of it.

Genetic and biochemical perturbations were used to test causality. The authors assessed TFEB and TFE3 dephosphorylation, PPP2/PP2A involvement, and the contribution of specific SQSTM1 phosphorylation sites. Mutational analysis identified serines 24 and 226 as critical for the ability of SQSTM1 to activate both AMPK and NFE2L2; these site-specific conclusions are described in the reference paper. The inclusion of cellular models such as mouse embryonic fibroblasts, together with cancer-relevant systems, strengthened the mechanistic analysis while still requiring caution when extrapolating to human tumors.

Protocol Parameters

• Stress condition: Establish a defined low-nutrient or low-glucose condition and compare it with a matched nutrient-replete control. The reference study uses metabolic stress as the initiating variable rather than treating AMPK activation as an isolated pharmacological event.
• Pathway readouts: Measure SQSTM1 abundance and phosphorylation together with AMPK and NRF2 pathway outputs. Total SQSTM1 should not be interpreted as equivalent to active SQSTM1 without phosphorylation or functional analysis.
• Lysosomal assessment: Pair lysosomal acidification perturbation with measurements of TFEB/TFE3 phosphorylation, KEAP1 turnover, and AXIN–STK11–AMPK complex formation. This arrangement helps distinguish lysosomal signaling from nonspecific toxicity.
• Mechanistic controls: Include ROS suppression, calcium-channel or lysosomal perturbation where appropriate, and SQSTM1 site-directed mutants when testing pathway order. These are replication-planning recommendations derived from the study’s logic, not universal conditions for every cell model.
• Metabolite control: Consider extracellular acidification and lactate-derived proton effects when interpreting low-glucose experiments. The reference study reports that protons supplied by lactic acid abrogated the stress responses, making medium composition a critical experimental variable.

Core Findings and Why They Matter

First, metabolic stress increased SQSTM1 expression and phosphorylation, and this response was necessary for coordinated activation of AMPK and NFE2L2/NRF2. SQSTM1-mediated KEAP1 degradation explains the NRF2 component, while lysosomal recruitment of the AXIN–STK11–AMPK complex explains the AMPK component. The two branches therefore converge at SQSTM1 but remain mechanistically distinguishable.

Second, AMPK was not merely a downstream target. Its activity contributed to the production and modification of SQSTM1, establishing the positive-feedback structure. This finding helps explain how cancer cells can maintain antioxidant defense under persistent metabolic pressure, even when the original stress signal is not acutely severe.

Third, lysosomal pH emerged as a regulatory variable. Low glucose metabolism and AMPK-dependent proton reduction caused lysosomal deacidification, which promoted PPP2/PP2A-dependent dephosphorylation of TFEB and TFE3. These transcription factors then supported SQSTM1 expression. In parallel, ROS and pH-dependent lysosomal calcium release activated MAP3K7/TAK1, increasing SQSTM1 phosphorylation. The model links energy status, proton handling, calcium signaling, and redox state in one pathway.

Finally, the requirement for SQSTM1 phosphorylation at S24 and S226 adds molecular precision to the feedback model. The findings suggest that SQSTM1 is regulated not only by its expression level or autophagic cargo function but also by stress-responsive phosphorylation. Functionally, this dual activation of AMPK and NRF2 can synergize antioxidant defense and support tumor growth under metabolic stress. That interpretation is relevant to cancer biology, but it does not by itself establish a clinical treatment strategy.

Comparison with Existing Internal Articles

The internal article AMPK–SQSTM1 Double-Positive Feedback Drives Antioxidant Synergy provides a concise overview of the same study’s central feedback-loop concept. The present analysis extends that framing by emphasizing experimental logic: KEAP1 degradation and lysosomal AMPK activation are parallel SQSTM1 outputs, while TFEB/TFE3 and MAP3K7/TAK1 explain how metabolic stress regulates SQSTM1 itself. The two articles are therefore complementary rather than independent sources of evidence.

Limitations and Transferability

The study offers a strong mechanistic model, but several boundaries should be maintained. Metabolic stress in cultured cells does not reproduce the full tumor microenvironment, where nutrient gradients, immune signals, extracellular matrix, and fluctuating oxygen levels may alter AMPK, NRF2, and lysosomal behavior. Mouse embryonic fibroblasts are useful for pathway reconstruction but are not equivalent to STK11- or KEAP1-altered human lung cancer cells.

The work also supports pathway interpretation more directly than clinical prediction. Co-occurring STK11 and KEAP1 mutations are consistent with compensatory stress adaptation, but the feedback model does not prove that every tumor with these alterations depends on SQSTM1 phosphorylation at the same level. In addition, pharmacological manipulation of lysosomal acidification, ROS, or proton balance can produce broad cellular effects. Genetic rescue, site-specific mutants, and multiple cellular backgrounds are therefore important for confirming pathway specificity.

Transferability to other stress-response systems should likewise be tested rather than assumed. The paper establishes a connection among AMPK, SQSTM1, KEAP1, NRF2, lysosomal pH, and MAP3K7/TAK1 under metabolic stress; it does not demonstrate that the same circuit controls unrelated ion channels or sensory signaling pathways.

Research Support Resources

Why this cross-domain matters, maturity, and limitations

For separate sensory neuron signaling studies and pain mechanism research, researchers can use AMG 9810 (SKU B7018), a selective competitive TRPV1 antagonist. The product information describes its use in inhibition of capsaicin-induced calcium influx and a CGRP release inhibition assay in cultured rat dorsal root ganglion neurons, making it relevant to sensory neuron signaling studies. This compound was not used in the reference paper, and the AMPK–SQSTM1–NRF2 feedback mechanism should not be presented as evidence for a TRPV1 effect. Accordingly, AMG 9810 is best treated as a separate TRPV1 antagonist tool for research rather than a reagent for reproducing the metabolic-stress experiments described here.